CLINICAL TRIALS PROFILE FOR RIFATER
✉ Email this page to a colleague
All Clinical Trials for RIFATER
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00948077 ↗ | Pharmacokinetic Study for Anti-tuberculosis Drugs | Unknown status | Taipei Medical University WanFang Hospital | N/A | 2009-07-01 | The purpose of this study is to evaluate the effect of food on pharmacokinetic profile of multiple doses orally administered first-line anti-tuberculosis drugs in subjects with pulmonary tuberculosis. |
| NCT01287221 ↗ | Study of Rifampicin in Multiple System Atrophy | Terminated | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 3 | 2011-03-01 | The purpose of this study was to determine whether Rifampicin was effective in slowing or reversing the progression of multiple system atrophy (MSA). Research studies indicate that there is an abnormality in protein synthesis and structure in parts of the brain responsible for MSA (protein misfolding) and the drug Rifampicin could potentially prevent or reverse this protein alteration. The study was done on participants with early MSA. The study consisted of taking the drug 2 times a day for 12 months. Participants underwent an evaluation of symptoms and function and will underwent a neurologic examination at the beginning of the study, at 6 months and at 12 months. They were also be contacted at 3 and 9 months by telephone. Studies were done at 10 participating sites. |
| NCT01287221 ↗ | Study of Rifampicin in Multiple System Atrophy | Terminated | Rare Disease Research Network Autonomic Consortium | Phase 3 | 2011-03-01 | The purpose of this study was to determine whether Rifampicin was effective in slowing or reversing the progression of multiple system atrophy (MSA). Research studies indicate that there is an abnormality in protein synthesis and structure in parts of the brain responsible for MSA (protein misfolding) and the drug Rifampicin could potentially prevent or reverse this protein alteration. The study was done on participants with early MSA. The study consisted of taking the drug 2 times a day for 12 months. Participants underwent an evaluation of symptoms and function and will underwent a neurologic examination at the beginning of the study, at 6 months and at 12 months. They were also be contacted at 3 and 9 months by telephone. Studies were done at 10 participating sites. |
| NCT01287221 ↗ | Study of Rifampicin in Multiple System Atrophy | Terminated | Vanderbilt University | Phase 3 | 2011-03-01 | The purpose of this study was to determine whether Rifampicin was effective in slowing or reversing the progression of multiple system atrophy (MSA). Research studies indicate that there is an abnormality in protein synthesis and structure in parts of the brain responsible for MSA (protein misfolding) and the drug Rifampicin could potentially prevent or reverse this protein alteration. The study was done on participants with early MSA. The study consisted of taking the drug 2 times a day for 12 months. Participants underwent an evaluation of symptoms and function and will underwent a neurologic examination at the beginning of the study, at 6 months and at 12 months. They were also be contacted at 3 and 9 months by telephone. Studies were done at 10 participating sites. |
| NCT01287221 ↗ | Study of Rifampicin in Multiple System Atrophy | Terminated | Phillip Low | Phase 3 | 2011-03-01 | The purpose of this study was to determine whether Rifampicin was effective in slowing or reversing the progression of multiple system atrophy (MSA). Research studies indicate that there is an abnormality in protein synthesis and structure in parts of the brain responsible for MSA (protein misfolding) and the drug Rifampicin could potentially prevent or reverse this protein alteration. The study was done on participants with early MSA. The study consisted of taking the drug 2 times a day for 12 months. Participants underwent an evaluation of symptoms and function and will underwent a neurologic examination at the beginning of the study, at 6 months and at 12 months. They were also be contacted at 3 and 9 months by telephone. Studies were done at 10 participating sites. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RIFATER
Condition Name
Clinical Trial Locations for RIFATER
Trials by Country
Clinical Trial Progress for RIFATER
Clinical Trial Phase
Clinical Trial Sponsors for RIFATER
Sponsor Name
| Sponsor Name for RIFATER | |
| Sponsor | Trials |
| Taipei Medical University WanFang Hospital | 1 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 1 |
| Rare Disease Research Network Autonomic Consortium | 1 |
| [disabled in preview] | 2 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
